Oregon Health & Science University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oregon Health & Science University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014348
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oregon Health & Science University (OHSU), a subsidiary of Oregon State University is an academic health center that provides medical education, research, patient care and community services. The center’s educational institute offers undergraduate and graduate courses in anesthesiology, dermatology, neurology, psychiatry, periodontology and nursing. It grants doctoral degrees in medicine, dentistry and nursing. OHSU provides healthcare services such as bone and joint care, cancer care, heart care, neuroscience, pediatrics, spine care and women’s health, among others. OHSU conducts research in disease areas including cancer, rare genetic disorders, diseases of the central nervous system, cardiovascular-related research and infectious disease. The center has campuses in Beaverton and Scappoose. OHSU is headquartered in Portland, Oregon, the US.

Oregon Health & Science University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Oregon Health & Science University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Oregon Health & Science University, Medical Devices Deals, 2011 to YTD 2017 10
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
MediciNova Enters into Agreement with US Department of Veterans and Oregon Health & Science 13
Vir Biotechnology Expands Agreement with Oregon Health & Science University 14
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 15
OncoResponse Enters into Agreement with OHSU Knight Cancer Institute 16
Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 17
Immunovia Partners with OHSU Knight Cancer Institute 18
Salem Health to Form Joint Venture with Oregon Health & Science University 19
Oregon Health Enters Into Co-Development Agreement With Intel 20
Organovo Enters Into Co-Development Agreement With OHSU Knight Cancer Institute For Cancer Research 21
Legacy Health System Partners OHSU Knight Cancer Institute 22
FEI And Oregon Health & Science University Partner To Create Living Lab For Cell Biology 23
Licensing Agreements 25
Quickbeam Enters into Licensing Agreement with Oregon Health & Science University 25
Fennec Pharma Expands Licensing Agreement with Oregon Health & Science University 26
Oregon Health and Science University Enters Into Option Agreement With Regen BioPharma To License Stem Cell IP 27
TomegaVax Enters into Licensing Agreement with Oregon Health and Science University 28
UbiVac CMV Enters into Licensing Agreement with Oregon Health & Science University 29
GenTel BioSciences Enters Into Licensing Agreement With Oregon Health 30
Oregon Health & Science University – Key Competitors 31
Oregon Health & Science University – Key Employees 32
Oregon Health & Science University – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Joint Venture 34
Recent Developments 35
Government and Public Interest 35
Oct 27, 2017: Johns Hopkins Partnering with Other Institutions to Create a National Center for Health Data 35
Oct 10, 2017: National MS Society Commits Nearly $14 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever 36
Oct 02, 2017: TSRI Researchers Join National Digital Health Informatics Collaborative 37
Sep 18, 2017: Study uncovers markers for severe form of multiple sclerosis 38
Sep 15, 2017: New funding to unite transatlantic forces for the early detection of cancer 39
Aug 02, 2017: Study in Nature demonstrates method for repairing genes in human embryos that prevents inherited diseases 40
Jan 30, 2017: New genome-mapping technique opens new avenues for precision medicine 42
Oct 20, 2016: Positive clinical trial results on gene transfer to treat macular degeneration 43
Oct 17, 2016: FDA awards 21 grants to stimulate product development for rare diseases 44
Oct 05, 2016: Study shows potential disease treatment in newborns via drug delivery to amniotic fluid 46
Jul 11, 2016: Discovery of insulin-producing beta cell subtypes may impact diabetes treatment 47
Apr 06, 2016: Researchers visualize brain’s serotonin pump, provide blueprint for new, more effective SSRIs 48
Mar 21, 2016: Giving antibodies to infant macaques exposed to an HIV-like virus could clear the infection 49
Other Significant Developments 51
Oct 18, 2017: Patients with Serious Mental Health Conditions Receive Preventive Care at Rates Similar to Those Without These Conditions 51
Oct 20, 2016: Accelerator Expands Operations with New Research Institution Partners 52
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Oregon Health & Science University, Pharmaceuticals & Healthcare, Key Facts 2
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Oregon Health & Science University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Oregon Health & Science University, Deals By Therapy Area, 2011 to YTD 2017 9
Oregon Health & Science University, Medical Devices Deals, 2011 to YTD 2017 10
Oregon Health & Science University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MediciNova Enters into Agreement with US Department of Veterans and Oregon Health & Science 13
Vir Biotechnology Expands Agreement with Oregon Health & Science University 14
NanoString Technologies Enters into Agreement with OHSU Knight Cancer Institute 15
OncoResponse Enters into Agreement with OHSU Knight Cancer Institute 16
Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 17
Immunovia Partners with OHSU Knight Cancer Institute 18
Salem Health to Form Joint Venture with Oregon Health & Science University 19
Oregon Health Enters Into Co-Development Agreement With Intel 20
Organovo Enters Into Co-Development Agreement With OHSU Knight Cancer Institute For Cancer Research 21
Legacy Health System Partners OHSU Knight Cancer Institute 22
FEI And Oregon Health & Science University Partner To Create Living Lab For Cell Biology 23
Quickbeam Enters into Licensing Agreement with Oregon Health & Science University 25
Fennec Pharma Expands Licensing Agreement with Oregon Health & Science University 26
Oregon Health and Science University Enters Into Option Agreement With Regen BioPharma To License Stem Cell IP 27
TomegaVax Enters into Licensing Agreement with Oregon Health and Science University 28
UbiVac CMV Enters into Licensing Agreement with Oregon Health & Science University 29
GenTel BioSciences Enters Into Licensing Agreement With Oregon Health 30
Oregon Health & Science University, Key Competitors 31
Oregon Health & Science University, Key Employees 32
Oregon Health & Science University, Other Locations 33
Oregon Health & Science University, Subsidiaries 33
Oregon Health & Science University, Joint Venture 34

★海外企業調査レポート[Oregon Health & Science University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Jungbunzlauer Suisse AG:企業の戦略・SWOT・財務情報
    Jungbunzlauer Suisse AG - Strategy, SWOT and Corporate Finance Report Summary Jungbunzlauer Suisse AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sberbank Rossii:企業の戦略・SWOT・財務情報
    Sberbank Rossii - Strategy, SWOT and Corporate Finance Report Summary Sberbank Rossii - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • ARxIUM-医療機器分野:企業M&A・提携分析
    Summary ARxIUM, formerly Intelligent Hospital Systems Inc, a subsidiary of Van Humbeck Family, is a medical device company that designs and manufactures automated solutions for the hospital pharmacy. The company’s products include RxWorks pro, workflow, inventory management, IV compounding system, h …
  • Acasti Pharma Inc (ACST)-製薬・医療分野:企業M&A・提携分析
    Summary Acasti Pharma Inc (Acasti), a subsidiary of Neptune Technologies & Bioressources Inc is a biopharmaceutical company that offers research, development and commercialization of prescription drugs. The company offers products such as Onemia and CaPre. Its CaPre is developed for the prevention a …
  • Garden Fresh Restaurant Corp:企業の戦略・SWOT・財務情報
    Garden Fresh Restaurant Corp - Strategy, SWOT and Corporate Finance Report Summary Garden Fresh Restaurant Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • RPC Group Plc:企業の戦略的SWOT分析
    RPC Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Swift Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Swift Biosciences Inc (Swift Biosciences) is a biotechnology company that develops novel research reagents, protocols, and molecular diagnostic tools. The company offers products such as 2S DNA library kit, 2S plus DNA library kit, 2S PCR-free DNA library kit, methyl-seq DNA library kit, DNA …
  • Human Care HC AB:企業の戦略的SWOT分析
    Human Care HC AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • CohBar Inc (COB.U):企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • TMX Group Ltd (X)
    TMX Group Ltd (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Xeikon N.V.:企業の戦略的SWOT分析
    Xeikon N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Pirelli & C. S.p.A.:企業の戦略・SWOT・財務情報
    Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • British Gas Ltd-エネルギー分野:企業M&A・提携分析
    Summary British Gas Limited (British Gas), a subsidiary of Centrica plc, is an energy utility company that undertakes the distribution of gas and electricity. It supplies electricity and gas to residential retail; commercial wholesale; and small, medium and large industrial customers. The company al …
  • Asiana Airlines Inc.:企業の戦略・SWOT・財務情報
    Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report Summary Asiana Airlines Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Alabama Power Co:発電所・企業SWOT分析
    Alabama Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • A. Menarini Diagnostics Srl-医療機器分野:企業M&A・提携分析
    Summary A. Menarini Diagnostics Srl (Menarini Diagnostics), a subsidiary of A Menarini Industrie Farmaceutiche Riunite Srl is a medical device company that offers in-vitro diagnostic products. The company provides pharmaceutical testing products including home glucose testing products, oral anticoag …
  • Complix NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Complix NV (Complix) is a biopharmaceutical company that discovers and develops alphabodies and pre-clinical programs. The company’s products comprise CMPX-1023, a novel alphabody for autoimmune diseases, and cell penetrating alphabodies for the treatment of cancer, among others. It designs …
  • OAO Tatneft:企業の戦略・SWOT・財務情報
    OAO Tatneft - Strategy, SWOT and Corporate Finance Report Summary OAO Tatneft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Imagion Biosystems Inc-医療機器分野:企業M&A・提携分析
    Summary Imagion Biosystems Inc (Imagion Biosystems), formerly Senior Scientific LLC, a subsidiary of Manhattan Scientifics Inc, is a biomedical equipment provider that offers nanomagnetic particle detection systems. The company offers nanomagnetic relaxometry method for cancer detection and precisio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆